RadNet (NASDAQ:RDNT) Stock Gets Price Target Increase from KeyCorp

RadNet (NASDAQ:RDNT) had its price objective raised by equities research analysts at KeyCorp from $92.00 to $95.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. KeyCorp‘s target price indicates a potential upside of 21.20% from the stock’s current price.

Several other research analysts have also recently commented on the company. Truist Financial boosted their price target on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Barclays raised their price objective on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Raymond James Financial restated a “strong-buy” rating on shares of RadNet in a research note on Tuesday, September 22nd. Jefferies Financial Group restated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a research report on Wednesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $90.43.

RadNet Stock Performance

Shares of RDNT stock opened at $78.38 on Tuesday. RadNet has a 12 month low of $50.82 and a 12 month high of $85.84. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a market capitalization of $6.17 billion, a P/E ratio of -290.29 and a beta of 1.42. The company’s fifty day moving average price is $72.64 and its two-hundred day moving average price is $65.43.

RadNet (NASDAQ:RDNT) last posted its quarterly earnings data on Sunday, November 8th. The medical research company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 EPS. On average, research analysts anticipate that RadNet will post 0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Edgestream Partners L.P. bought a new stake in shares of RadNet in the 3rd quarter worth about $245,000. Teachers Retirement System of The State of Kentucky lifted its position in shares of RadNet by 14.1% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 44,580 shares of the medical research company’s stock worth $3,073,000 after purchasing an additional 5,504 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of RadNet by 5.2% during the third quarter. HighTower Advisors LLC now owns 11,012 shares of the medical research company’s stock worth $759,000 after purchasing an additional 542 shares during the last quarter. White Pine Capital LLC acquired a new position in RadNet in the third quarter worth about $2,462,000. Finally, Bessemer Group Inc. grew its stake in RadNet by 19.3% in the third quarter. Bessemer Group Inc. now owns 474,120 shares of the medical research company’s stock worth $32,684,000 after purchasing an additional 76,737 shares in the last quarter. 77.90% of the stock is owned by institutional investors and hedge funds.

RadNet News Summary

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: Adjusted EPS of $0.30 beat the $0.22 consensus by about 35%. Revenue rose 22.1% year over year to $638.3 million, and the company reported record quarterly revenue and adjusted EBITDA. RadNet Q3 results and updated guidance
• Positive Sentiment: RadNet raised its FY 2026 outlook for the third consecutive quarter, with revenue guidance of $2.5 billion–$2.6 billion, versus a consensus estimate around $2.5 billion. Higher guidance signals continued confidence in growth. RadNet Q3 earnings and raised guidance
• Positive Sentiment: An analyst highlighted the ONRAD acquisition as a potential value and growth driver: it expands RadNet’s inpatient presence and geographic reach, and ONRAD’s reported EBITDA margins above 30% could make the deal margin-accretive. Advanced imaging growth, operating leverage and AI-related cost controls were also cited as supporting profitability. Analyst view on RadNet’s earnings and acquisition
• Negative Sentiment: Quarterly revenue of $638.3 million came in slightly below analysts’ $640.0 million estimate, tempering an otherwise strong report. RadNet quarterly earnings report

RadNet Company Profile

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.